Research programme: NeuGene antisense compounds - Sarepta Therapeutics
Alternative Names: AVI 4179; AVI 4451; AVI 4XXX; NeuBioticsLatest Information Update: 18 Apr 2013
At a glance
- Originator AVI BioPharma
- Developer Sarepta Therapeutics
- Class Antisense oligonucleotides; Morpholines
- Mechanism of Action Genetic transcription inhibitors; HMG-CoA reductase inhibitors; Intercellular adhesion molecule 3 antagonists; Intercellular adhesion molecule-1 antagonists; NF-kappa B inhibitors; Nitric oxide synthase inhibitors; Proto-oncogene protein c-myc modulators; RNA interference; RNA synthesis inhibitors; Testosterone congener inhibitors; Transforming growth factor beta stimulants; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Anthrax; Bacterial infections; Ricin poisoning
- Discontinued Coronary artery restenosis; Hypercholesterolaemia; Immunological disorders; Inflammation; Multiple sclerosis; Prostate cancer; Stem cell mobilisation